Loading quotes...

Forecast

The analysts' average price target is €19.79 (+23.15%). The median is €18.75 (+16.68%).

Buy	5
Hold	7
Sell	1

News Go to news feed

Viatris raises guidance after Q2 growth and gains FDA approval for contraceptive patch

Viatris reported Q2 revenue up about 4.9% year over year and management raised fiscal 2026 guidance across key metrics. Billionaire-led funds held stakes in the stock as it traded near $16, up ~33% year-to-date. The FDA approved the once-weekly Gwyn Lo contraceptive patch, a fast-acting meloxicam formulation is under review and two late-stage trials (selatogrel and cenerimod) will report in early fiscal 2027. Valuation looks attractive (forward non-GAAP P/E ~6.6, EV/EBITDA ~7) but tariff risk and looming changes to generic exemptions in 2028 pose material downside for its import-reliant portfolio. » More on finance.yahoo.com
Viatris beats Q2 expectations and raises full-year outlook

Viatris reported adjusted EPS of $0.69 for Q2 2026 (expectation $0.61) and revenue of $3.76 billion versus expected $3.67 billion, and subsequently raised its full-year guidance. Free cash flow and margins improved; adjusted EBITDA was $1.2 billion and gross margin rose to 57.5%. Debt fell to about 2.9x. The stock dipped slightly premarket as investors weighed potential H2 risks such as a new procurement policy in China, production interruptions in Nashik and intensified competition. » More on de.investing.com
Viatris receives FDA approval for once-weekly contraceptive patch Gwyn Lo

The FDA has approved Gwyn Lo, a once-weekly contraceptive patch from Viatris containing norelgestromin and ethinylestradiol. The patch is intended for women of childbearing potential with a BMI under 30 kg/m² and delivers 220 mcg norelgestromin and 20 mcg ethinylestradiol per day. Approval was based on the Phase III Luminous study, which showed a Pearl Index of 4.14 and complete detachment of only 1.3% of applied systems. Common side effects included application-site reactions, irregular and heavy withdrawal bleeding, and nausea; Gwyn Lo is contraindicated in smokers over 35 and in women with BMI ≥30 kg/m². Viatris expects to launch the product later this year. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, VIATRIS INC. O.N. has already paid €0.30 in dividends. The last payout was in September.

Financials

In the last quarter, VIATRIS INC. O.N. had revenue of €3.29bn and net profit of -€104.09m

(EUR)	June 2026	YoY
Revenue	3.29bn	8.31%
Gross profit	1.28bn	12.85%
Net profit	-104.09m	2,567.20%
EBITDA	638.76m	30.30%

Fundamentals

Metric	Value
Market capitalization	€18.52bn
Number of shares	1.15bn
52-week high/low	€16.74 - €7.31
Dividend yield	2.59%
Dividends TTM	€0.42
Beta	0.86
P/E ratio	-50.18
PEG ratio	-3.44
P/B ratio	1.47
P/S ratio	1.41

Company profile

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Name	VIATRIS INC. O.N.
CEO	Scott Andrew Smith
Headquarters	Canonsburg, pa USA
Website	viatris.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	17/03/1980
Employees	30,000